Imagine using goats as living factories to make expensive medicine. Instead of using giant metal vats and complex chemicals, this method lets goats produce the drug naturally in their milk. It is like switching from a high-maintenance factory to a natural farm, making life-saving treatments much cheaper and greener.
Traditional biopharmaceutical manufacturing using CHO cells is too expensive and carbon-intensive, making biosimilars unaffordable for many markets, especially in low- and middle-income countries.
A bioproduction platform using CRISPR-Cas9 engineered goats to produce monoclonal antibodies in milk, including plans for an industrial processing plant.
If you are a drug developer dealing with the high cost of CHO cell production — this project developed a goat-based platform that reduces API costs from €100-200 to €25 per gram. This allows for the creation of affordable generics for blockbusters like adalimumab.
If you are a manufacturer dealing with massive setup costs — this project developed a production method that reduces CAPEX from €200-300 million to 35 million. This significantly lowers the barrier to entry for building new production facilities.
If you are a company dealing with high carbon emissions in drug making — this project developed a system with a 1000x lower CO2 footprint, reducing emissions from 25T to 5 per Kg of API. This helps companies meet strict sustainability targets.
The BioMilk platform reduces the cost of the active pharmaceutical ingredient (API) from €100-200 down to €25 per gram.
Yes, the project includes scaling up a goat facility and building an industrial milk processing plant to enable large volume production.
Bio-Sourcing plans to license biosimilars around Phase 1, receiving upfront payments and milestones totaling €40M per biosimilar, plus a 5% royalty on net sales.
The company aims to bring its first biosimilar to clinical trials by 2027.
The first target is adalimumab, with plans to follow with trastuzumab and golimumab.
The project is led by a single Belgian SME, Bio-Sourcing, which holds 100% of the industry share. This lean structure suggests a highly centralized control of the IP and a focused execution strategy, though it lacks academic or large-scale industrial partners within the formal consortium.
Contact Bio-Sourcing in Belgium for licensing opportunities regarding the BioMilk platform.
Contact us to explore partnerships with Bio-Sourcing for biosimilar API sourcing.
